Analyst Juan C. Sanabria of BMO Capital maintained a Hold rating on Global Medical REIT, retaining the price target of $7.50.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Juan C. Sanabria has given his Hold rating due to a combination of factors including the alignment of Global Medical REIT’s second quarter 2025 financial results with market expectations. The company’s Funds from Operations (FFO) per share was consistent with analysts’ predictions, and the adjusted FFO showed a modest year-over-year increase. However, the Funds Available for Distribution (FAD), which now includes capital expenditures, fell short of the market’s expectations, indicating potential concerns about cash flow management.
Furthermore, the company’s guidance for adjusted FFO in 2025 remains slightly above market consensus, suggesting cautious optimism about future performance. Despite this, there are strategic uncertainties, such as the anticipated asset sales aimed at reducing leverage, which could be dilutive. Additionally, the board’s recent decision to significantly cut the dividend and the upcoming leasing risks contribute to a more conservative outlook, justifying the Hold rating.
In another report released on July 25, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $7.50 price target.